Press Releases Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
10.54 ^USD	-1.40%		+4.46%	+15.44%

May. 09	Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting	May. 15	GL
Phathom Pharmaceuticals : First Quarter 2024 Earnings Call – May 2024	May. 09	PU
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	May. 09	GL
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024	Apr. 29	GL
Phathom Pharmaceuticals : Corporate Overview – April 2024	Apr. 12	PU
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	GL
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	AQ
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, 'VOQUEZNA Can Kick Some Acid'	Mar. 27	AQ
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”	Mar. 26	GL
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 07	GL
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024	Feb. 29	GL
Phathom Pharmaceuticals Announces VOQUEZNA Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	Feb. 14	AQ
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	Feb. 13	GL
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	Feb. 13	AQ
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	GL
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	AQ
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital	Dec. 14	GL
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	Dec. 07	AQ
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	Dec. 06	GL
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn	Nov. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Press Releases

Filters